These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 17703370

  • 1. Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience.
    Grigorescu Sido P, Drugan C, Cret V, Al-Kzouz C, Denes C, Coldea C, Zimmermann A.
    J Inherit Metab Dis; 2007 Oct; 30(5):783-9. PubMed ID: 17703370
    [Abstract] [Full Text] [Related]

  • 2. Baseline characteristics and outcome in Romanian patients with Gaucher disease type 1.
    Grigorescu-Sido P, Drugan C, Alkhzouz C, Zimmermann A, Coldea C, Denes C, Grigorescu MD, Cret V, Bucerzan S.
    Eur J Intern Med; 2010 Apr; 21(2):104-13. PubMed ID: 20206881
    [Abstract] [Full Text] [Related]

  • 3. [Alglucerase treatment of type I Gaucher's disease. Preliminary results in Spain. Spanish Group on Gaucher's Disease].
    Pérez-Calvo JI, Giraldo P, Giralt M.
    Sangre (Barc); 1997 Jun; 42(3):189-94. PubMed ID: 9381260
    [Abstract] [Full Text] [Related]

  • 4. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM.
    Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
    [Abstract] [Full Text] [Related]

  • 5. Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months.
    Pastores GM, Sibille AR, Grabowski GA.
    Blood; 1993 Jul 15; 82(2):408-16. PubMed ID: 8392397
    [Abstract] [Full Text] [Related]

  • 6. Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years.
    Hollak CE, Belmatoug N, Cole JA, Vom Dahl S, Deegan PB, Goldblatt J, Rosenbloom B, van Dussen L, Tylki-Szymańska A, Weinreb NJ, Zimran A, Cappellini MD.
    Br J Haematol; 2012 Aug 15; 158(4):528-38. PubMed ID: 22640238
    [Abstract] [Full Text] [Related]

  • 7. Enzyme replacement and substrate reduction therapy for Gaucher disease.
    Shemesh E, Deroma L, Bembi B, Deegan P, Hollak C, Weinreb NJ, Cox TM.
    Cochrane Database Syst Rev; 2015 Mar 27; 2015(3):CD010324. PubMed ID: 25812601
    [Abstract] [Full Text] [Related]

  • 8. Plasma chitotriosidase activity versus CCL18 level for assessing type I Gaucher disease severity: protocol for a systematic review with meta-analysis of individual participant data.
    Raskovalova T, Deegan PB, Yang R, Pavlova E, Stirnemann J, Labarère J, Zimran A, Mistry PK, Berger M.
    Syst Rev; 2017 Apr 20; 6(1):87. PubMed ID: 28427477
    [Abstract] [Full Text] [Related]

  • 9. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL.
    Clin Ther; 2012 Feb 20; 34(2):259-71. PubMed ID: 22264444
    [Abstract] [Full Text] [Related]

  • 10. Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial.
    Lukina E, Watman N, Dragosky M, Lau H, Avila Arreguin E, Rosenbaum H, Zimran A, Foster MC, Gaemers SJM, Peterschmitt MJ.
    Am J Hematol; 2019 Jan 20; 94(1):29-38. PubMed ID: 30264864
    [Abstract] [Full Text] [Related]

  • 11. Serum chitotriosidase activity in Gaucher patients on enzyme replacement therapy (ERT).
    Czartoryska B, Tylki-Szymańska A, Górska D.
    Clin Biochem; 1998 Jul 20; 31(5):417-20. PubMed ID: 9721443
    [Abstract] [Full Text] [Related]

  • 12. Enzyme replacement therapy for Gaucher disease in Australia.
    Goldblatt J, Szer J, Fletcher JM, McGill J, Rowell JA, Wilson M.
    Intern Med J; 2005 Mar 20; 35(3):156-61. PubMed ID: 15737135
    [Abstract] [Full Text] [Related]

  • 13. Effect of treatment on biclonal gammopathy associated with Gaucher disease.
    Decaux O, Ruelland A, Grosbois B.
    J Inherit Metab Dis; 2007 Oct 20; 30(5):824. PubMed ID: 17879146
    [Abstract] [Full Text] [Related]

  • 14. The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations.
    Piran S, Roberts A, Patterson MA, Amato D.
    Blood Cells Mol Dis; 2009 Oct 20; 43(3):289-93. PubMed ID: 19793665
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry.
    Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Zimran A.
    Am J Med; 2002 Aug 01; 113(2):112-9. PubMed ID: 12133749
    [Abstract] [Full Text] [Related]

  • 16. Therapeutic goals in Gaucher disease.
    Mistry P, Germain DP.
    Rev Med Interne; 2006 Mar 01; 27 Suppl 1():S30-8. PubMed ID: 16644400
    [Abstract] [Full Text] [Related]

  • 17. Recombinant macrophage targeted enzyme replacement therapy for Gaucher disease in India.
    Nagral A, Mewawalla P, Jagadeesh S, Kabra M, Phadke SR, Verma IC, Puri RD, Gupta N, Kishnani PS, Mistry PK.
    Indian Pediatr; 2011 Oct 01; 48(10):779-84. PubMed ID: 22080680
    [Abstract] [Full Text] [Related]

  • 18. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
    Ben Turkia H, Gonzalez DE, Barton NW, Zimran A, Kabra M, Lukina EA, Giraldo P, Kisinovsky I, Bavdekar A, Ben Dridi MF, Gupta N, Kishnani PS, Sureshkumar EK, Wang N, Crombez E, Bhirangi K, Mehta A.
    Am J Hematol; 2013 Mar 01; 88(3):179-84. PubMed ID: 23400823
    [Abstract] [Full Text] [Related]

  • 19. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources.
    Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA, Parker C, Schiffmann R, Hill SC, Brady RO.
    Ann Intern Med; 1995 Jan 01; 122(1):33-9. PubMed ID: 7985893
    [Abstract] [Full Text] [Related]

  • 20. Enzyme replacement therapy with imiglucerase in Taiwanese patients with type I Gaucher disease.
    Hsu CC, Chien YH, Lai MY, Hwu WL.
    J Formos Med Assoc; 2002 Sep 01; 101(9):627-31. PubMed ID: 12645190
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.